During October 24-27, 2024, the pre-market clinical data for the YonFlow® flow diverter was officially released at the Oriental Conference on Cerebrovascular Diseases 2024 (OCIN 2024). 

、This prospective, multicenter, randomized, positive-controlled study includes 14 research centers in China, covering the treatment of large and small aneurysms. The primary endpoint of the study is the complete occlusion rate of aneurysms at 6 months, and the secondary endpoints include the occlusion rate at 12 months and other safety indicators. 

The study results show that the complete occlusion rate at 6 months for patients with small aneurysms reached 82.35%, and the occlusion rate further increased to 87.50% at 12 months. In the treatment of large aneurysms, the complete occlusion rates at 6 months for the experimental group and the control group were 74.55% and 69.61%, respectively, and the occlusion rates at 12 months were 84.11% and 79.38%, respectively. In terms of safety, both groups had similar incidence rates of stroke related to the affected vessels and target vessel bleeding, with no significant differences